COPENHAGEN, Denmark, October 18 /PRNewswire/ -- Tamas Bartfai, Ph.D., is the director of the Harold L. Dorris Neurological Research Center at The Scripps Research Institute, La Jolla, CA. In addition, he holds the Harold L. Dorris Chair in Neuroscience. Professor Bartfai is former head of central nervous system research at Hoffman-La Roche where he served as Senior Vice President. Previously, he was at Stockholm University, as Chairman, Department of Neurochemistry and Neurotoxicity. Born in Budapest, Hungary, he received his undergraduate education there at Eotvos Lorand University and a Ph.D. in biochemistry at Stockholm. Dr. Bartfai is a Board Member of a number of US Biotech firms and advises a number of large investment banks on Pharma/Biotech.
"We are delighted and honored to welcome Tamas Bartfai to our Board of Directors", says Claes Post, CEO of Gastrotech. "Professor Bartfai brings tremendous experience and knowledge to our Board. This will be a great help in our on-going process of bringing our clinical stage programs forward towards proof of concept".
Professor Olle Isaksson, Chairman of the Board of Directors of Gastrotech Pharma A/S adds: "Professor Bartfai is known for his extensive insight into many of the key aspects of drug development. He will strengthen our board tremendously and provide us with excellent connections to his wide-spread network."
About Gastrotech Pharma A/S
Gastrotech Pharma A/S is a biopharmaceutical company focusing on medical applications of gastrointestinal hormones. The company is founded on the basis of research carried out at the medical faculty of Gothenburg University. The scientists are world leading experts in the field of endocrinology and have made ground breaking contributions to the field through pre-clinical and clinical studies. Professor John-Olov Jansson, Professor Olle Isaksson and co-workers are among the founders of the company. Gastrotech Pharma develops pharmaceutical products for clinical evaluation in several diseases of large unmet medical needs to significantly improve the patient's quality of life.
Gastrotech has two programs in clinical development: GLP-1 for Irritable Bowel Syndrome, and Ghrelin for the treatment of cachexia and other catabolic syndromes. More information is available at http://www.gastrotechpharma.com/.
CONTACT: For further information contact: Claes Post, CEO, GastrotechPharma A/S, at +45-33-44-42-42